The Practice of Medicinal Chemistry

Edited by

CAMILLE G. WERMUTH
Laboratoire de Pharmacochimie Moléculaire, Faculté de Pharmacie,
Université Louis Pasteur, Illkirch, France

ACADEMIC PRESS
Harcourt Brace and Company, Publishers
London San Diego New York
Boston Sydney Tokyo Toronto
Contents

Contributors ix
Foreword xiii
Preface xv

Part I: General Aspects of Medicinal Chemistry

1 Medicinal chemistry: Definition and objectives. Drug and disease classifications 3
Camille G. Wermuth

2 Discovering new drugs: the legacy of the past, present approaches, and hopes for the future 11
Philippe Meyer

3 Measurement and expression of drug effects 25
Jean-Paul Kan

4 The three main phases of drug activity: the pharmaceutical, the pharmacokinetic and the pharmacodynamic phases 41
Camille G. Wermuth

Part II: Drug Targets and Lead Compound Discovery Strategies

5 Drug targets—molecular mechanisms of drug action 55
Jean-Pierre Gies

6 Strategies in the search for new lead compounds or original working hypotheses 81
Camille G. Wermuth
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Author(s)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Natural products as pharmaceuticals and sources for lead structures</td>
<td>David G.I. Kingston</td>
<td>101</td>
</tr>
<tr>
<td>2</td>
<td>Combinatorial libraries and high-throughput synthesis</td>
<td>Sheila Hobbs de Witt</td>
<td>117</td>
</tr>
<tr>
<td>3</td>
<td>Synthesis of peptide libraries for lead structure screening</td>
<td>Victor J. Hruby</td>
<td>135</td>
</tr>
<tr>
<td>4</td>
<td>The contribution of molecular biology to drug discovery</td>
<td>Adrian N. Hobden</td>
<td>153</td>
</tr>
<tr>
<td>5</td>
<td>Electronic screening: Lead finding from database mining</td>
<td>Hans-Peter Weber</td>
<td>167</td>
</tr>
</tbody>
</table>

**Part III: Primary Exploration of Structure–Activity Relationships**

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Author(s)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>Molecular variations in homologous series: Vinylogues and benzologues</td>
<td>Camille G. Wermuth</td>
<td>181</td>
</tr>
<tr>
<td>7</td>
<td>Molecular variations based on isosteric replacements</td>
<td>Camille G. Wermuth</td>
<td>203</td>
</tr>
<tr>
<td>8</td>
<td>Ring transformations</td>
<td>Camille G. Wermuth</td>
<td>239</td>
</tr>
<tr>
<td>9</td>
<td>Identical and nonidentical twin drugs</td>
<td>Jean-Jacques Bourguignon</td>
<td>261</td>
</tr>
<tr>
<td>10</td>
<td>Application strategies for primary structure–activity relationship exploration</td>
<td>Camille G. Wermuth</td>
<td>295</td>
</tr>
</tbody>
</table>

**Part IV: Substituents and Functions: Qualitative and Quantitative Aspects of Structure–Activity Relationships**

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Author(s)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>Specific substituent effects</td>
<td>Camille G. Wermuth</td>
<td>311</td>
</tr>
<tr>
<td>12</td>
<td>The role of functional groups in drug–receptor interactions</td>
<td>Peter R. Andrews</td>
<td>345</td>
</tr>
<tr>
<td>13</td>
<td>Quantitative approaches to structure–activity relationships</td>
<td>Han van de Waterbeemd</td>
<td>367</td>
</tr>
</tbody>
</table>

**Part V: Spatial Organization, Receptor Mapping and Molecular Modelling**

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Author(s)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>14</td>
<td>Stereochemical aspects of drug action I: Conformational restriction, steric hindrance and hydrophobic collapse</td>
<td>Phillip A. Hart and Daniel H. Rich</td>
<td>393</td>
</tr>
<tr>
<td>15</td>
<td>Stereochemical aspects of drug action II: Optical isomerism</td>
<td>Miklós Simonyi and Gábor Maksay</td>
<td>413</td>
</tr>
</tbody>
</table>
Contents vii

22 Pharmacophore identification and receptor mapping 437
Hans-Dieter Hölting

23 Three-dimensional quantitative structure–activity relationships: D₂ dopaminergic agonists as an example 459
Yvonne Connolly Martin and C. Thomas Lin

24 The use of X-ray structures of receptors and enzymes in drug discovery 485
Jean-Michel Rondeau and Herman Schreuder

25 Protein homology modelling and drug discovery 523
Marcel F. Hibert

26 The transition from agonist to antagonist activity: Symmetry and other considerations 547
David J. Triggle

27 Design of peptidomimetics 571
Hiroshi Nakanishi and Michael Kahn

Part VI: Chemical Modifications Influencing the Pharmacokinetic Properties

28 The fate of xenobiotics in living organisms 593
Frans M. Belpaire and Marc G. Bogaert

29 Biotransformation reactions 615
Camille G. Wermuth and Bernard Testa

30 Chemical aspects of biotransformations leading to toxic metabolites 643
André Picot and Anne-Christine Macherey

31 Designing prodrugs and bioprecursors I: Carrier prodrugs 671
Camille G. Wermuth, Jean-Cyr Gaignault and Christian Marchandeau

32 Designing prodrugs and bioprecursors II: Bioprecursor prodrugs 697
Camille G. Wermuth

33 Macromolecular carriers for drug targeting 717
Etienne H. Schacht, Stefan Vansteenkiste and Len Seymour

Part VII: Pharmaceutical and Chemical Formulation Problems

34 Preparation of water-soluble compounds through salt formation 739
Bradley D. Anderson and Karl P. Flora

35 Preparation of water-soluble compounds by covalent attachment of solubilizing moieties 755
Camille G. Wermuth

36 Drug solubilization with organic solvents, or using micellar solutions or other colloidal dispersed systems 777
Kurt H. Bauer

37 Improvement of drug properties by cyclodextrins 793
Kaneto Uekama and Fumitoshi Hirayama
38 Chemical and physicochemical solutions to formulation problems
   Camille G. Wermuth

Part VIII: Development of New Drugs: Legal and Economic Aspects

39 From discovery to market availability
   Jacques A. Dangoumau

40 Drug nomenclature
   Sabine Kopp-Kubel

41 Legal aspects of product protection – what a medicinal chemist
   should know about patent protection
   Maria Souleau

42 The consumption and production of pharmaceuticals
   Bryan G. Reuben

Index

939

A colour plate section can be found between pages 446 and 447.